SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 208 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $336 | -68.0% | 559,731 | -30.6% | 0.03% | -72.4% |
| Q2 2023 | $1,049 | +171.8% | 806,954 | +268.3% | 0.10% | +176.3% |
| Q1 2023 | $386 | -38.6% | 219,088 | +9.3% | 0.04% | -51.3% |
| Q4 2022 | $629 | -99.2% | 200,465 | +1232.0% | 0.08% | +680.0% |
| Q3 2022 | $74,000 | -21.3% | 15,050 | -33.9% | 0.01% | -28.6% |
| Q2 2022 | $94,000 | -55.0% | 22,785 | -36.7% | 0.01% | -50.0% |
| Q1 2022 | $209,000 | -27.9% | 35,978 | +11.6% | 0.03% | -6.7% |
| Q3 2021 | $290,000 | +215.2% | 32,240 | +215.4% | 0.03% | -41.2% |
| Q2 2020 | $92,000 | +8.2% | 10,223 | +0.3% | 0.05% | +410.0% |
| Q4 2019 | $85,000 | -86.3% | 10,189 | -84.3% | 0.01% | -84.1% |
| Q1 2019 | $620,000 | -31.3% | 65,031 | -17.3% | 0.06% | -39.4% |
| Q4 2018 | $902,000 | +104.5% | 78,600 | +238.5% | 0.10% | +352.2% |
| Q1 2018 | $441,000 | -55.8% | 23,221 | -63.5% | 0.02% | -42.5% |
| Q1 2015 | $997,000 | +261.2% | 63,576 | +316.9% | 0.04% | +100.0% |
| Q1 2014 | $276,000 | – | 15,249 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |